Optimal sampling scheme in men with abnormal multiparametric MRI undergoing MRI-TRUS fusion prostate biopsy

Prostate cancer is the most common cancer in men with an estimated incidence of over 164,000 new cases in 2018 in the United States [1]. As multiparametric magnetic resonance imaging (mpMRI) is becoming more available, the use of MRI-transrectal ultrasound (TRUS) fusion targeted prostate biopsy (TBx) is rising and has the potential of becoming the new standard of care [2].

Source: Urologic Oncology: Seminars and Original Investigations - November 13, 2018 Category: Urology & Nephrology Authors: Yuval Freifeld, Yin Xi, Niccolo Passoni, Solomon Woldu, Brad Hornberger, Kenneth Goldberg, Aditya Bagrodia, Ganesh Raj, Vitaly Margulis, Jeffrey A. Cadeddu, Yair Lotan, Franto Francis, Ivan Pedrosa, Claus G. Roehrborn, Daniel N. Costa Tags: Original article Source Type: research